Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus

Isabel Gallego, Julie Sheldon, Elena Moreno, Josep Gregori, Josep Quer, Juan Ignacio Esteban, Charles M. Rice, Esteban Domingo, Celia Perales

Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; Liver Unit, Internal Medicine, Laboratory of Malalties Hepàtiques, Vall d’Hebron Institut de Recerca-Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Roche Diagnostics, S.L., Sant Cugat del Vallés, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA

Sofosbuvir displays a high phenotypic barrier to resistance, and it is a component of several combination therapies for hepatitis C virus (HCV) infections. HCV fitness can be a determinant of decreased sensitivity to direct-acting antiviral agents such as telaprevir or daclatasvir, but fitness-dependent decreased drug sensitivity has not been established for drugs with a high phenotypic barrier to resistance. Low- and high-fitness HCV populations and biological clones derived from them were used to infect Huh-7.5 hepatoma cells. Sofosbuvir efficacy was analyzed by measuring virus progeny production during several passages and by selection of possible sofosbuvir resistance mutations determined by sequencing the NS5B-coding region of the resulting populations. Sofosbuvir exhibited reduced efficacy against high-fitness HCV populations, without the acquisition of sofosbuvir-specific resistance mutations. A reduced sofosbuvir efficacy, similar to that observed with the parental populations, was seen for high-fitness individual biological clones. In independently derived high-fitness HCV populations or clones passaged in the presence of sofosbuvir, M289L was selected as the only substitution in the viral polymerase NS5B. In no case was the sofosbuvir-specific resistance substitution S282T observed. High HCV fitness can lead to decreased sensitivity to sofosbuvir, without the acquisition of specific sofosbuvir resistance mutations. Thus, fitness-dependent drug sensitivity can operate with HCV inhibitors that display a high barrier to resistance. This mechanism may underlie treatment failures not associated with selection of sofosbuvir-specific resistance mutations, linked to in vivo fitness of pretreatment viral populations.

Hepatitis C virus (HCV) infection affects about 2.3% of the world population, with treatment and patient management costs being an important burden for health systems (1). Treatment efficacy, quantified as the rate of sustained viral response, has improved markedly with the introduction of direct-acting antiviral agents (DAAs) (2). DAAs include inhibitors of the viral protease NS3-4A (telaprevir [TPV], boceprevir, simeprevir, paritaprevir/ritonavir, asunaprevir, etc.), of nonstructural protein NS5A (daclatasvir [DCV], ledipasvir, ombitasvir, etc.), and the polymerase NS5B (nonnucleoside analogues, such as dasabuvir, and one nucleoside analogue, such as sofosbuvir [SOF]). Many DAAs have been licensed for human use, and others are still in preclinical and clinical assessment.

A major issue in antiviral treatments is the selection of inhibitor-resistant mutants leading to treatment failure. Selection is influenced by genetic and phenotypic barriers to resistance. The genetic barrier depends on the number and type of mutations needed for the RNA to encode amino acid substitutions needed to confer resistance. The phenotypic barrier is determined by the fitness cost inflicted upon the virus by the mutations associated with resistance. Barriers vary depending on the nature of the antiviral agent, the viral genomic nucleotide sequence, and population parameters. For statistical reasons a large, replicating viral population increases the likelihood that required mutations will occur with genomes harboring fitness-restoring compensatory mutations (reviewed in reference 3). In the case of HCV, inhibitors of NS3-4A and NS5A and nonnucleoside inhibitors of NS5B generally exhibit a low phenotypic barrier to resistance while nucleoside analogues display a high barrier (4–8).

Recent results suggest that HCV fitness may be a determinant of decreased sensitivity to antiviral agents (9). Passage of the parental population HCV (passage 0, p0) [based on the JFH-1-based chimera Jc1FLAG2(p7-nsGluc2A)] in Huh-7.5 reporter cells resulted in increased fitness, as expected from continued virus replication in the same environment (3). Fitness levels of the populations at passage 45 (HCV p45) and at passage 100 (HCV p100) were 1.9 ± 0.3 and 2.2 ± 0.4, respectively, relative to the fitness of HCV p0 (fitness 1). These fitness increases were accompanied by an expansion of the mutant spectrum, with a minimum mutation frequency increase of 1.7-fold and 2.6-fold for HCV p45 and HCV p100, respectively, relative to HCV p0 (9). These populations exhibited decreased sensitivity to the anti-HCV inhibitors TPV, DCV, cyclosporine (CsA), ribavirin (RBV), and alpha interferon (IFN-α) (9, 10). In no case was resistance associated with specific mutations in the viral genome. Further proof was pro-
vided by parallel kinetics of progeny production over a 1,000-fold range of multiplicities of infection (MOIs) in the presence of the drugs and by maintenance of the resistance phenotypes in biological clones isolated from the passaged HCV populations (9). It was concluded that fitness or a fitness-associated trait was a drug resistance determinant for HCV (9, 11, 12). This prior study did not examine a DAA with a high phenotypic resistance barrier such as SOF, the prodrug of β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine, which, in its triphosphate form, acts as chain terminator during HCV RNA elongation (13, 14). SOF has been used in monotherapy and in various combinations with ribavirin and other DAAs (ledipasvir, sofosbuvir, etc.) with average sustained virological response (SVR) rates exceeding 90% (see, for example, references 15 to 20, among others). Mutations associated with SOF resistance have been described previously. Substitution S282T in NS5B, which confers resistance to 2′-C-methylated nucleotide analogues, was first described in replicon assays (21) and subsequently selected in vitro using HCV replicons of genotypes 1 to 6 (22). For genotype 1a, S282T was also found in combination with I434M. For genotype 2a, substitution T179A, M289L, or I293L was required for resistance together with S282T, while substitutions M343T and H479P increased the replication capacity of replicons carrying S282T (23). Regarding SOF resistance in vivo, NS5B S282T has been found in a patient infected with HCV genotype 2b who relapsed after SOF monotherapy in a phase 2 trial (17). In another study, 99.8% of the viral population harbored the S282T substitution after 4 weeks of SOF monotherapy, despite the low frequency of the mutant at baseline (24). S282T was also found in one subject who relapsed 4 weeks after SOF monotherapy (25) and in two patients infected with genotype 1 who did not achieve a sustained virological response after treatment with SOF/RBV (26) or SOF/ledipasvir (19). Recently, substitutions S282G/C/R were detected in nine patients, and in silico models suggest that these substitutions may be associated with SOF resistance (27). A mutant with a L159F/L320F double substitution emerged in one genotype 1b-infected patient, and the virus showed reduced susceptibility to SOF and mericitabine in cell culture (28). HCV genotype 3 with NS5B substitutions L159F and V321A were isolated from patients in phase 3 clinical trials with SOF-based regimens, but these substitutions did not affect overall susceptibility to SOF; in other patients that presented partial responses or relapse to SOF treatment, NS5B substitutions found included L159F, C316N, S282R, and/or L320F, but their clinical significance has not been established (reviewed in reference 29). Structural bioinformatic analyses from next-generation sequencing (NGS) data of virus from patients participating in clinical trials with SOF confirmed that substitutions L159F, V321A, C316N, and S282R were associated with treatment failure (7). Thus, despite a generally accepted high phenotypic barrier to achieve SOF resistance, both in vitro assays and clinical results suggest that a number of substitutions in NS5B—which differ depending on the viral genotype—can confer diminished susceptibility to this inhibitor, with S282T playing a key role (30).

Given the remarkable clinical impact of SOF-based HCV treatments, it was of interest to investigate if passaged, high-fitness HCV populations displayed decreased sensitivity to SOF in the absence of SOF-specific resistance mutations. In the present report we show that this is indeed the case, suggesting that inherent pretreatment fitness of HCV can alter sensitivity to sofosbuvir-based regimens, without the need for selection of specific resistance mutants.

MATERIALS AND METHODS

Cells, viruses, infections, and titration of infectivity. The origin of the Huh-7 Lunet, Huh-7.5, and Huh-7.5 reporter cell lines, conditions for their growth, preparation of HCV, and titration of infectivity have been described previously (9, 10, 31–33). Huh-7 Lunet cells were used for electroporation of RNA transcribed from plasmid Jc1FLAG2(p7-nsGluc2A) (genotype 2a) or its GNN replication-defective mutant used as a negative control (10). Supernatants of the passaged electroporated cells were pooled, the virus was concentrated 20-fold, and the concentrate was used to infect Huh-7.5 reporter cells to prepare the parental virus HCV p0; further details are described in Perales et al. (10). HCV p0 was subjected to 100 serial passages in Huh-7.5 reporter cells. For the first passage, 4 × 10^5 Huh-7.5 reporter cells were infected with HCV p0 at a multiplicity of infection (MOI) of 0.5 50% tissue culture infective doses (TCID_{50}/cell). For subsequent passages, the same numbers of cells were infected with the virus contained in 0.5 ml of cell culture supernatant from the previous infection; at passage 60 the volume of supernatant used for infection was diluted gradually up to 20-fold to limit cytopathology. The MOIs at different passages ranged from 0.2 to 5 TCID_{50}/cell. Passage (p) numbers are identified as follow: HCV p45 and HCV p100 are the HCV p0 population subjected to 45 and 100 serial passages, respectively, in Huh-7.5 reporter cells.

To titrate HCV infectivity, viral samples were serially diluted and added to Huh-7.5 cells seeded 15 h earlier in 96-well plates (6,400 cells/well). At 3 days postinfection, the cells were washed with phosphate-buffered saline (PBS), fixed with cold methanol, and stained with anti-NS5A monoclonal antibody 9E10 (10, 33).

Sofosbuvir treatment. A stock solution of 10 mM SOF (Selleck Chemicals) was prepared in dimethyl sulfoxide (DMSO) and stored at −80°C. Prior to use, the solution was diluted in Dulbecco’s modified Eagle’s medium (DMEM) to reach the desired concentration. SOF toxicity (the SOF concentration needed to kill 50% of the cells, or cytotoxic concentration 50 [CC_{50}]) and inhibitory activity (the SOF concentration needed to inhibit the infectious progeny production by 50% [IC_{50}]) were measured as previously described (9).

Preparation of biological clones from hepatitis C virus populations. HCV p0, HCV p45, and HCV p100 were treated with mild detergent (sodium deoxycholate at 0.01%) for 10 min at room temperature, diluted, and applied to Huh-7.5 cell monolayers in M96 wells. The cell culture supernatant of a well with a single cluster of Huh-7.5-infected cells was used to infect 1 × 10^5 Huh-7.5 cells in an M24 well, followed by an infection of 4 × 10^5 Huh-7.5 cells in an M6 dish. Finally, 1 × 10^5 Huh-7.5 cells were infected in a 60 dish under standard infection conditions (9).

RNA extraction, cDNA synthesis, PCR amplification, and nucleotide sequencing. Intracellular viral RNA was extracted from infected cells at each passage using a Qiagen RNaseasy kit (Qiagen, Valencia, CA), according to the manufacturer’s instructions. HCV RNA was reverse transcribed using avian myeloblastosis (AMV) reverse transcriptase (Promega), and the PCR amplification of the NS5B-coding region was carried out using AccuScript (Agilent Technologies) with oligonucleotide primers Jc1-NS5B-F1, 5′-TGGTCTACTTGTCGCCAGGAG (sense orientation; the 5′ nucleotide corresponds to genomic residue 7625), and Jc1-NS5B-R4, 5′-AGTATCGTATGGAGTGACTTAG (antisense orientation; the 5′ nucleotide corresponds to genomic residue 9476; residue numbering is parallel to other nucleotide sequences determined on the two strands of the amplified DNA according to standard procedures (10, 34).

Statistical analyses. To determine the statistical significance of differences in serial-passage experiments, two-way analysis of variance...
RESULTS

Dose-dependent inhibition of HCV by sofosbuvir in cell culture. To quantify the toxicity of SOF for Huh-7.5 reporter cells and its inhibitory activity on progeny production by the parental HCV p0 population, CC<sub>50</sub> and IC<sub>50</sub> were obtained (Fig. 1A and B). The IC<sub>50</sub> (20 ± 3 nM) was at least 2,000-fold higher than the CC<sub>50</sub> (>50 μM), yielding a therapeutic index (TI), defined as CC<sub>50</sub>/IC<sub>50</sub>, of >2,000. The TI value allowed exploration of the inhibitory effect over a 12-fold range of SOF concentrations in the course of three serial passages of HCV p0 (Fig. 1C). The results indicate a dose-dependent inhibition of HCV p0 progeny production under conditions of undetectable toxicity for the host Huh-7.5 reporter cells.

Resistance to sofosbuvir of multiply passaged HCV p0. To test if passaged HCV displayed resistance to SOF, HCV p0, HCV p45, and HCV p100 were subjected to 10 serial infections in the absence or presence of SOF (800 nM and 1,200 nM sofosbuvir (SOF)). For the first passage, 4 × 10<sup>5</sup> Huh-7.5 reporter cells were infected with 1.2 × 10<sup>5</sup> TCID<sub>50</sub> of the indicated virus, to give a multiplicity of infection (MOI) of 0.03 TCID<sub>50</sub>/cell. For successive infections, 4 × 10<sup>5</sup> Huh-7.5 reporter cells were infected with the virus contained in 500 μl of the cell culture supernatant from the previous infection, yielding a range of MOIs of 1.25 × 10<sup>-2</sup> to 3.95 TCID<sub>50</sub>/cell. Infections were allowed to proceed for 72 h. The abscissa axes indicate the limits of detection of virus titers. Infection conditions are further detailed in Materials and Methods.

4 but survival of HCV p45 and HCV p100, with at least a 10<sup>3</sup>-fold higher progeny production than that of HCV p0 (the difference of progeny production between HCV p45 or HCV p100 and HCV p0 was statistically significant [P < 0.001; ANOVA test], but the difference between results with HCV p45 and HCV p100 was not statistically significant [P > 0.05; ANOVA test]). In the presence of 1,200 nM SOF, the three populations were inhibited; but while the infectivity of HCV p0 was not detectable by passage 2, HCV p100 survived at least during five passages, and HCV p45 increased its viral production from passages 8 to 10 (Fig. 2) (the difference in progeny production between HCV p45 and HCV p100 or HCV p0 was statistically significant [P < 0.001; ANOVA test], but the difference between HCV p0 and HCV p100 was not significant [P > 0.05; ANOVA test]). Thus, HCV passaged in cell culture in the absence of SOF exhibited significant resistance to SOF.

Mutations in the NS5B-coding regions of high-fitness HCV populations passaged in the absence or presence of sofosbuvir. The consensus sequence of the NS5B-coding region of HCV p0, HCV p45, and HCV p100 did not reveal detectable substitutions previously associated with SOF resistance, except for T179A present in ∼50% of genomes in HCV p100 (Fig. 3). T179A has not been considered a SOF resistance substitution per se in the absence of S282T. When tested as a single replacement, T179A remained at low frequency levels at passage 5 in the presence of 800 nM SOF and was undetectable by passage 10. Instead, M289L was dominant at passage 10 (Fig. 3). When HCV p100 was subjected to five
clones was 8.5-fold and 100.9-fold, respectively, higher than the average production by the HCV p0 clones (P = 0.7 and P = 0.02, respectively; ANOVA test) (Fig. 4). Since minority HCV genomes harboring a SOF resistance mutation should have been excluded by the cloning process, this result suggests that viral fitness or a fitness-related trait can confer SOF resistance to HCV without the presence of specific SOF resistance mutations. This differential sensitivity to SOF did not vary over the 630,000-fold range of MOI values involved in the passages (Fig. 4).

Evidence of a dual fitness-dependent mechanism of drug resistance. To investigate the possible selection of SOF resistance mutations during passage of biological clones in the presence of SOF, the NS5B-coding regions of clones passaged in the absence or presence of SOF that yielded sufficient viral RNA were sequenced. The results indicate that in some (but not all) populations, mutations leading to an amino acid substitution previously related to SOF resistance were selected, reaching partial or complete dominance (Fig. 5). The most significant substitutions were T179A and M289L, for opposite reasons. In our experimental system T179A can be excluded as a bona fide SOF resistance mutation because it occurred only in a biological clone from HCV p0 in the absence and presence of SOF. M289L became partially or totally dominant in two out of the six clones tested and always in the presence of SOF. In no case was the SOF resistance substitution S282T selected (Fig. 5). In conclusion, high HCV basal fitness is a factor of diminished sensitivity to SOF and a parameter that can promote selection of specific mutations related to SOF resistance.

DISCUSSION

In this report we have documented a fitness-dependent resistance to the high-barrier anti-HCV DAA SOF. This drug was chosen because of its importance in current HCV therapies (e.g., references 15 to 20 and 35 to 40). The results show that HCV p45 and HCV p100 are significantly more resistant than HCV p0 to SOF. A comparison with the previous results with other inhibitors shows quantitative differences. While the inhibition by IFN-α, ribavirin, TPV, DCV, and CsA was 513-, 412-, 453-, 13,658-, and 309-fold, respectively, greater for HCV p0 than HCV p100, for SOF this difference was only 34-fold (compare Fig. 2 with Fig. 3 in reference 9). For this comparison, the drug concentrations used were 6.0- to 50-fold higher than the corresponding IC_{50}s, and titers were measured at passage 3 in infections carried out at an MOI of 0.03 TCID_{50}/cell. Additional work is needed to determine if the lower difference observed with SOF than with the other DAAs may relate to its higher resistance barrier.

In a study with HCV genotype 2a replicons, Lam and colleagues observed that the major SOF resistance substitution S282T was selected only when replicon carrier cells were treated with SOF concentrations that were 70-fold higher than the IC_{50} (23). Since the SOF concentrations used in our HCV inhibition experiments were 32- to 48-fold higher than the IC_{50}, it is not unexpected that S282T was not selected in any of the populations or biological clones passaged in the presence of SOF.

The molecular basis and the possible clinical impact of the basal HCV fitness level on treatment response are unknown. Both in the cell culture system and among clinical samples of HCV, mutations that alter HCV fitness have been described (10, 41). As a possible mechanism, we proposed a competition between the number of replicating genomes at each replicative unit in an-in
fected cell and the concentration of inhibitor that reaches the repli-
cative units (9). This model is plausible if viral fitness is essen-
tially due to increased intracellular viral replication. The other
model is an increased stability of the replication complex, with
longer time for the functional HCV RNA to decay away in the
absence of replication. Experiments to test these possibilities are in
progress. Regarding the possible clinical significance of our find-
ings, the main difficulty is to estimate the basal HCV fitness at the
onset of the treatment. Theoretical studies have inferred fitness
landscapes from sequence data, but the majority of them have
ignored intrahost heterogeneity and have regarded viruses as
"strains" rather than mutant clouds. An interesting approach has
been taken by N. Beerenwinkel and colleagues to infer fitness
landscapes from deep-sequencing data (42, 43). They likened
HIV-1 fitness parameters to the mutant spectrum composition
using quasispecies theory with a number of assumptions to permit
the computation (mutation-selection equilibrium, use of a limited
haplotype subset, uniform mutation rate, etc.). Use of these
computational tools together with clinical data that may be asso-
ciated with high HCV fitness (duration of the infection, viral load,
and mutant spectrum complexity) (44, 45) may provide a predic-
tive tool for inhibitor resistance independent of specific muta-
tions, and such efforts are in progress.

It has been observed that treatment failures are more frequent
in patients that have remained infected for a long time, and it has
been well established that prolonged infections in the same envi-
nronment result in a fitness gain (reviewed in reference 3). There is
recent evidence of patients that do not respond to treatment in
whom resistance mutations are not detected after HCV rebound.
In a cohort of 1,797 patients subjected to TPV monotherapy, 28%
were nonresponders, and the virus in 23% did not include detect-
table TPV resistance mutations (46). In a large cohort of 1,662
patients treated with SOF either alone or in combination with
ribavirin or ribavirin and pegylated IFN-α, 18% of patients did
not attain an SVR; in many cases treatment failure could not be
attributed to specific resistance mutations (25). The authors pro-
posed that residual HCV replication might occur in the liver dur-
ing drug treatment, with undetectable RNA in the blood. Other
modeling studies have shown that low-level virus replication may
occur in the presence of inhibitor, without the selection of drug-
resistant variants (47). In some patients that did not respond to a
combination of TPV, pegylated IFN-α, and ribavirin, no resis-
tance mutations were detected (48). In another study, no SOF
resistance mutations were observed after virological relapse of
HCV genotype 2 in patients subjected to SOF-based combination
therapies (49).

If a fitness-related mechanism of decreased HCV sensitivity
operated in vivo, it would mean that some treatment failures are
expected, independent of specific resistance mutations. The fit-
ness cost of resistance mutations and fitness rescue due to com-
parative mutations are two well-established mechanisms by
which fitness can impact the development of antiviral resistance.
The results presented here introduce new roles of fitness in con-
nection with the management of HCV infections: a direct influ-
ence on multidrug resistance and the enhanced probability that
high fitness, by virtue of its associated capacity to explore sequence
space, can promote selection of drug resistance mutations or mu-
tations that facilitate the selection of bona fide resistance muta-
tions. It should be noted that current standard methodologies to
assess the influence of specific mutations identified in break-

---

**FIG 4** Infectious progeny production of biological clones of hepatitis C virus passaged in the absence or presence of sofosbuvir. Biological clones and their parental populations are indicated in the upper boxes, and the absence or presence of sofosbuvir (SOF) is indicated at left. For the first passage, $4 \times 10^3$ Huh-7.5

---

**TABLE 1** Summary of clinical trials for the treatment of hepatitis C virus (HCV) infection with sofosbuvir (SOF) and ribavirin (RBV). The table shows the percentage of patients who achieved sustained virological response (SVR) according to different treatment regimens and the presence of resistance mutations.

<table>
<thead>
<tr>
<th>Treatment Regimen</th>
<th>SVR (%)</th>
<th>Resistance Mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOF + RBV</td>
<td>90</td>
<td>No</td>
</tr>
<tr>
<td>SOF + RBV + pegylated IFN-α</td>
<td>85</td>
<td>No</td>
</tr>
<tr>
<td>SOF + RBV + pegylated IFN-α + RBV</td>
<td>80</td>
<td>No</td>
</tr>
</tbody>
</table>
the corresponding biological clones were retrieved (identified with the same absence or presence of sofosbuvir. The parental viral populations from which the merase)-coding region of biological clones of hepatitis C virus passaged in the liver environment (reviewed in reference 3). A major issue raised in the context of the infectious virus as it replicates in the natural culture. Such methods will not uncover possible fitness effects on subgenomic replicons and measuring their resistance levels in cell through viruses during treatment in HCV drug resistance consist of introducing the mutations in either infectious HCV clones or subgenomic replicons and measuring their resistance levels in cell culture. Such methods will not uncover possible fitness effects on resistance since fitness is dependent on the sequence and population context of the infectious virus as it replicates in the natural liver environment (reviewed in reference 3). A major issue raised by our study is that bona fide SOF-resistant variants may not be selected or even selectable under current anti-HCV regimens. However, differences in the treatment regimen and the duration necessary to achieve an SVR may be due to fitness differences in the starting viral population. This may underpin the decreased SVR efficacy associated with SOF for HCV genotype 3, with SOF requiring longer treatment durations or combination with additional DAAs.

Repeating an issue already raised during early days of the AIDS epidemic, the value of resistance testing is being debated for guiding HCV treatment decisions (50). As a general note, molecular information has always been beneficial to improving personalized antiviral treatments (reviewed in reference 3) unless pan-genomic, fully effective new combination treatments become available. The present study on fitness-dependent SOF resistance provides an additional incentive for resistance testing in patients: the possibility that treatment failure may occur in the absence of selection of mutants with specific resistance mutations. This information should contribute to a better understanding of the influence exerted by quasispecies dynamics in vivo and of treatment outcomes. Finally, the observations with HCV beg the question of possible fitness-dependent effects of inhibitor sensitivity in other viruses.

ACKNOWLEDGMENTS
Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by Instituto de Salud Carlos III. C.P. is supported by the Miguel Servet program of the Instituto de Salud Carlos III (CP14/00121).

FUNDING INFORMATION
This work, including the efforts of Charles Rice, was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (R01 AI099284). This work, including the efforts of Juan Ignacio Esteban, was funded by MINECO | Instituto de Salud Carlos III (ISICIII) (PI13/00456). This work, including the efforts of Rafael Esteban, was funded by MINECO | Instituto de Salud Carlos III (ISICIII) (PI15/00829). This work, including the efforts of Esteban Domingo, was funded by Ministerio de Economía y Competitividad (MINECO) (BFU-2011-23604). This work, including the efforts of Esteban Domingo, was funded by Ministerio de Economía y Competitividad (MINECO) (SAF2014-52400-R). This work, including the efforts of Esteban Domingo, was funded by Comunidad Autónoma de Madrid (S2013/ABI-2906).

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES


